BriaCell Unveils Promising Anti-Cancer Data for Bria-OTS+ Platform

BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an announcement.

BriaCell Therapeutics has presented promising preclinical data on its next-generation Bria-OTS+ platform at the SITC 2025 meeting, showcasing its rapid and durable anti-cancer activity. The platform, which activates both innate and adaptive immune responses, demonstrated increased tumor cell cytotoxicity in breast and prostate cancer models, suggesting broad applicability across multiple cancer types. These findings support the potential of Bria-OTS+ as a transformative cancer immunotherapy, with upcoming clinical trials planned for its lead candidates, Bria-BRES+ and Bria-PROS+.

The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company is known for its personalized off-the-shelf cancer immunotherapy platforms, specifically targeting breast and prostate cancer.

Average Trading Volume: 3,904

Technical Sentiment Signal: Sell

Current Market Cap: C$26.83M

See more insights into BCT stock on TipRanks’ Stock Analysis page.